{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"NRX Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"NRXP"},"Address":{"label":"Address","value":"1201 ORANGE STREET,SUITE 600, WILMINGTON, Delaware, 19801, United States"},"Phone":{"label":"Phone","value":"+1 484 254-6134"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour."},"CompanyUrl":{"label":"Company Url","value":"https://nrxpharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carrie M. Carretta","title":"Senior VP-Clinical Development & Medical Affairs"},{"name":"Jonathan C. Javitt","title":"Chairman & Chief Executive Officer"},{"name":"Martin Brecher","title":"Medical Director"},{"name":"Riccardo Panicucci","title":"Chief Technology Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}